[1] Office of the Commissioner. (2025, September 25). FDA and Kratom. U.S. Food And Drug Administration. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
[2] Kratom. (2022, March 25). National Institute on Drug Abuse. https://nida.nih.gov/research-topics/kratom
[3] Striley, C. W., Hoeflich, C. C., Viegas, A. T., Berkowitz, L. A., Matthews, E. G., Akin, L. P., Iheanyi-Okeahialam, C., Mansoor, U., & McCurdy, C. R. (2022). Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review. Substance Abuse Research and Treatment, 16. https://doi.org/10.1177/11782218221095873
[4] Striley, C. W., Hoeflich, C. C., Viegas, A. T., Berkowitz, L. A., Matthews, E. G., Akin, L. P., Iheanyi-Okeahialam, C., Mansoor, U., & McCurdy, C. R. (2022b). Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review. Substance Abuse Research and Treatment, 16. https://doi.org/10.1177/11782218221095873
[5] Smith, K. E., Sharma, A., Grundmann, O., & McCurdy, C. R. (2023). Kratom alkaloids: a blueprint? ACS Chemical Neuroscience, 14(2), 195–197. https://doi.org/10.1021/acschemneuro.2c00704
[6] Becker, D. E. (2012). Basic and Clinical Pharmacology of Autonomic Drugs. Anesthesia Progress, 59(4), 159–169. https://doi.org/10.2344/0003-3006-59.4.159
-